How Does Angiotensin II Cause Renal Injury?

Hypertension

Volumn 43, Issue 4, 2004, Pages 722-723

  Long, David A ^a   Price, Karen L ^a   Herrera Acosta, Jaime ^b   Johnson, Richard J ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

BLOOD PRESSURE; CARCASS; CHRONIC KIDNEY FAILURE; DIABETES MELLITUS; EDITORIAL; HYPERTENSION; KIDNEY BLOOD FLOW; KIDNEY FIBROSIS; KIDNEY INJURY; KIDNEY ISCHEMIA; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTECTION; PROTEIN FUNCTION; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HUMANS; HYPERTENSION; HYPERTENSION, RENAL; KIDNEY DISEASES; KIDNEY FAILURE; KIDNEY GLOMERULUS; MODELS, BIOLOGICAL; PEPTIDYL-DIPEPTIDASE A; RATS; RENAL CIRCULATION; RENIN-ANGIOTENSIN SYSTEM; VASOCONSTRICTION;

EID: 1642419670     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000120964.22281.3e     Document Type: Editorial

References (14)

1. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr., Jones DW, Materson BJ, Oparil S, Wright JT Jr., Roccella EJ. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA. 2003;289:2560-2572.
2. Rodriguez-Iturbe B, Pons H, Herrera-Acosta J, Johnson RJ. Role of immunocompetent cells in nonimmune renal diseases. Kidney Int. 2001;59:1626-1640.
3. Remuzzi G, Ruggenenti P, Perico N. Chronic renal disease: renoprotective benefits of renin-angiotensin system inhibition. Ann Intern Med. 2002;136:604-615.
4. Zanchetti A, Ruilope LM. Antihypertensive treatment in patients with type 2 diabetes mellitus: what guidance from recent controlled randomized trials? J Hypertens. 2002;20:2099-2110.
5. Bidani AK, Griffin KA. Long-term consequences of hypertension for normal and diseased kidneys. Curr Opin Nephrol Hypertens. 2002;11:73-80.
6. Bidani AK, Griffin KA, Bakris G, Picken MM. Lack of evidence of blood pressure-independent protection by renin-angiotensin system blockade after renal ablation. Kidney Int. 2000;57:1651-1661.
7. Griffin KA, Abu-Amarah I, Picken M, Bidani AK. Renoprotection by ACE inhibition or aldosterone blockade is blood pressure-dependent. Hypertension. 2003;41:201-206.
8. Kurtz TW. False claims of blood pressure-independent protection by blockade of the renin angiotensin aldosterone system? Hypertension 2003;41:193-196.
9. Ruilope LM. Comments on the renal aspects of the ALLHAT study. J Hypertens. 2003;21:235-236.
10. Eng E, Veniant M, Floege J, Fingerle J, Alpers CE, Menard J, Clozel JP, Johnson RJ. Renal proliferative and phenotypic changes in rats with two-kidney, one-clip Goldblatt hypertension. Am J Hypertens. 1994;7:177-185.
11. Mori T, Cowley AW Jr. Role of pressure in angiotensin II-induced renal injury: Chronic servo-control of renal perfusion pressure. Hypertension. 2004;752-759.
12. Franco M, Tapia E, Santamaria J, Zafra I, Garcia-Torres R, Gordon KL, Pons H, Rodriguez-Iturbe B, Johnson RJ, Herrera-Acosta J. Renal cortical vasoconstriction contributes to development of salt-sensitive hypertension after angiotensin II exposure. J Am Soc Nephrol. 2001;12:2263-2271.
13. Mazzali M, Kanellis J, Han L, Feng L, Xia YY, Chen Q, Kang DH, Gordon KL, Watanabe S, Nakagawa T, Lan HY, Jonson RJ. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol. 2002;282:F991-F997.
14. Kanellis J, Nakagawa T, Herrera-Acosta J, Schreiner GF, Rodriguez-Iturbe B, Jonson RJ. A single pathway for the development of essential hypertension. Cardiol Rev. 2003;11:180-196.